Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Tobias Paehler"'
Autor:
Thomas Kissner, Guenter Blaich, Andreas Baumann, Sven Kronenberg, Adam Hey, Andrea Kiessling, Petra M. Schmitt, Wouter Driessen, Chantal Carrez, Daniel Kramer, Jennifer Fretland, Wolfgang F. Richter, Tobias Paehler, Ulrike Hopfer, Benno Rattel
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
New challenges and other topics in non-clinical safety testing of biotherapeutics were presented and discussed at the nineth European BioSafe Annual General Membership meeting in November 2019. The session topics were selected by European BioSafe org
Externí odkaz:
https://doaj.org/article/488cd892d26c4d9eb1fc8b67023cf03e
Autor:
Jacques Rey, Franck Poitiers, Tobias Paehler, Aurélie Brunet, A. Thomas DiCioccio, Christopher P. Cannon, Howard K. Surks, Jean‐Louis Pinquier, Corinne Hanotin, William J. Sasiela
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 5, Iss 6 (2016)
BackgroundAlirocumab undergoes target‐mediated clearance via binding of proprotein convertase subtilisin/kexin type 9 (PCSK9). Statins increase PCSK9 levels; the effects of nonstatin lipid‐lowering therapies are unclear. Every‐4‐weeks dosing
Externí odkaz:
https://doaj.org/article/c518381745cb47939eff18a40e2c04b3
Autor:
Wolfgang F. Richter, Thomas Kissner, Adam Hey, Andrea Kiessling, Wouter H. P. Driessen, Petra M. Schmitt, Tobias Paehler, Jennifer Fretland, Chantal Carrez, Andreas Baumann, Daniel Kramer, Benno Rattel, Guenter Blaich, Sven Kronenberg, Ulrike Hopfer
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
New challenges and other topics in non-clinical safety testing of biotherapeutics were presented and discussed at the nineth European BioSafe Annual General Membership meeting in November 2019. The session topics were selected by European BioSafe org
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f30105996d25a6a92f4701b9beeb6a9a
http://europepmc.org/articles/PMC8274438
http://europepmc.org/articles/PMC8274438
Autor:
Tobias Paehler, Anne Lehmann, Thorsten Sadowski, Zoltan Lukacs, Sven Ruf, Jean-Louis Pinquier, Hartmut Ruetten, J. Tillner
Publikováno v:
Clinical Pharmacology in Drug Development. 5:57-68
Cathepsin A (CathA) is a lysosomal protein where it forms a stable complex with neuraminidase and ß-galactosidase. CathA also has enzymatic activity and is involved in the degradation of many peptides. CathA was recently discovered as a target for h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9f1f3bb66326b363820099f99e0a38e
https://doi.org/10.1002/cpdd.201
https://doi.org/10.1002/cpdd.201
Autor:
Christopher P. Cannon, A. Thomas DiCioccio, Jean-Louis Pinquier, William J. Sasiela, Jacques Rey, Corinne Hanotin, Aurélie Brunet, Tobias Paehler, Howard K. Surks, Franck Poitiers
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Alirocumab undergoes target‐mediated clearance via binding of proprotein convertase subtilisin/kexin type 9 ( PCSK 9). Statins increase PCSK 9 levels; the effects of nonstatin lipid‐lowering therapies are unclear. Every‐4‐weeks dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::248c809d0ead76a4b82ccd2935b16fdf
http://europepmc.org/articles/PMC4937273
http://europepmc.org/articles/PMC4937273
Publikováno v:
Bioanalysis. 2:1469-1475
Background: Dried blood spot (DBS) sampling could potentially become the preferred blood collection technique in toxicological and clinical studies. Autoradiography was performed to study compound distribution within a dbs under different conditions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::005f9bd70fea79b7b907478eb21ffcb5
https://doi.org/10.4155/bio.10.96
https://doi.org/10.4155/bio.10.96
Autor:
Tobias Paehler, Corinne Hanotin, Franck Poitiers, Bill Sasiela, Aurelie Brunet, Jean-Louis Pinquier, Jacques Rey
Publikováno v:
Journal of the American College of Cardiology. 63(12)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) monoclonal antibodies such as alirocumab undergo target mediated clearance by binding PCSK9. Statins are known to increase PCSK9; however, little is known about effects of ezetimibe (EZE) or fenof
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ea064997f287a7c1d1612f031a485d8
Autor:
Thomas Maier, Joachim Brendel, Andreas E. Busch, Klaus Wirth, Jennifer Frenzel, Tobias Paehler, Karsten Knobloch, Bjoern Rosenstein, Markus Bleich
Publikováno v:
Cardiovascular research. 60(2)
Objectives: AVE0118 is a novel blocker of the K+ channels Kv1.5 and Kv4.3 which are the molecular basis for the human cardiac ultrarapid delayed rectifier potassium current ( I Kur) and the transient outward current ( I to). The objective of this stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fcdbcf8c1f047edc2ed315610bf94e0
https://pubmed.ncbi.nlm.nih.gov/14613859
https://pubmed.ncbi.nlm.nih.gov/14613859
Autor:
Aurelie Brunet, Tobias Paehler, Jacques Rey, Pascale Lewanczyk, Franck Poitiers, Catherine Lunven, Corinne Hanotin, Bill Sasiela
Publikováno v:
Journal of the American College of Cardiology. (12):A1377
Alirocumab administered subcutaneously (SC) in the abdomen significantly reduced low-density lipoprotein cholesterol (LDL-C) in Phase 1 and 2 trials of up to 12 weeks duration. As patients may use different injection sites, the bioavailability of a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a4edd3486ef75b669798474c1803f87